xarelto (rivaroxoaban) is an oral blood-thinning medication jointly produced by pharmaceutical giants Bayer and Johnson & Johnson.
The drug was released to the market in 2011 and the FDA approved it as a blood-thinner thatis used to treat patients who are in danger of experiencing strokes.
However, despite its recent entry into the consumer drug market, xarelto has already been linked to a number of serious injuries with its users including blood clots—which are known to cause a blockage in the veins and potentially result in a fatality.
This anticoagulant has been linked to serious and even deadly side effects.
People who took xarelto and suffered from irreversible bleeding filed lawsuits for compensation for medical bills, injuries and emotional trauma. Families of people whose bleeds were fatal also sought justice for their loved ones. xarelto’s predecessor, Pradaxa, has already led to a number of lawsuits filed against its manufacturer because of complications such as excessive bleeding and death. Its maker paid $650 million dollars to settle about 4,000 claims.
Initiation of xarelto is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.
Public Article Source: http: //www. accessdata. fda. gov/ drugsatfda_docs/ label/ 2015/ 202439s015lbl. pdf